South State CORP. Has $2.84 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Share on StockTwits

South State CORP. trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 11.7% in the third quarter, HoldingsChannel reports. The firm owned 19,187 shares of the company’s stock after selling 2,535 shares during the period. South State CORP.’s holdings in Eli Lilly and were worth $2,841,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. DC Investments Management LLC boosted its stake in Eli Lilly and by 1.3% during the second quarter. DC Investments Management LLC now owns 5,186 shares of the company’s stock worth $851,000 after buying an additional 66 shares during the period. StoneX Group Inc. lifted its position in shares of Eli Lilly and by 1.3% during the second quarter. StoneX Group Inc. now owns 4,958 shares of the company’s stock worth $814,000 after purchasing an additional 66 shares during the last quarter. Hotaling Investment Management LLC lifted its position in shares of Eli Lilly and by 2.7% during the second quarter. Hotaling Investment Management LLC now owns 2,534 shares of the company’s stock worth $416,000 after purchasing an additional 67 shares during the last quarter. KMG Fiduciary Partners LLC lifted its position in shares of Eli Lilly and by 2.0% during the third quarter. KMG Fiduciary Partners LLC now owns 3,392 shares of the company’s stock worth $502,000 after purchasing an additional 67 shares during the last quarter. Finally, Fernwood Investment Management LLC lifted its position in shares of Eli Lilly and by 0.7% during the second quarter. Fernwood Investment Management LLC now owns 10,718 shares of the company’s stock worth $1,760,000 after purchasing an additional 70 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

In other Eli Lilly and news, SVP Melissa S. Barnes sold 5,000 shares of Eli Lilly and stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $151.01, for a total value of $755,050.00. Following the transaction, the senior vice president now owns 23,580 shares in the company, valued at $3,560,815.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.09% of the stock is owned by insiders.

Several research firms have recently weighed in on LLY. Morgan Stanley decreased their target price on Eli Lilly and from $176.00 to $170.00 and set an “overweight” rating for the company in a research report on Wednesday, October 28th. Sanford C. Bernstein began coverage on Eli Lilly and in a research report on Tuesday, November 10th. They set a “market perform” rating and a $150.00 target price for the company. Truist began coverage on Eli Lilly and in a research report on Friday, October 23rd. They set a “buy” rating and a $180.00 target price for the company. Mizuho decreased their target price on Eli Lilly and from $164.00 to $156.00 and set a “neutral” rating for the company in a research report on Tuesday, November 17th. Finally, Berenberg Bank assumed coverage on Eli Lilly and in a report on Tuesday, September 29th. They issued a “hold” rating and a $144.00 price objective for the company. One analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Eli Lilly and currently has an average rating of “Buy” and an average target price of $168.07.

LLY traded up $2.08 on Friday, hitting $145.49. The company had a trading volume of 5,064,305 shares, compared to its average volume of 3,964,550. The stock has a fifty day moving average price of $143.19 and a 200-day moving average price of $151.75. Eli Lilly and Company has a 12-month low of $113.29 and a 12-month high of $170.75. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.06 and a current ratio of 1.36. The stock has a market capitalization of $139.17 billion, a price-to-earnings ratio of 23.77, a P/E/G ratio of 1.35 and a beta of 0.27.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Sunday, November 1st. The company reported $1.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.17). Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.87 billion. During the same quarter last year, the firm earned $1.48 EPS. Eli Lilly and’s revenue for the quarter was up 4.8% on a year-over-year basis. Analysts forecast that Eli Lilly and Company will post 7.26 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a $0.74 dividend. The ex-dividend date of this dividend is Thursday, November 12th. This represents a $2.96 annualized dividend and a yield of 2.03%. Eli Lilly and’s dividend payout ratio (DPR) is presently 49.01%.

About Eli Lilly and

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia.

Featured Story: Understanding Specialty Certificates of Deposit

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.